Last reviewed · How we verify
Guna-Virus (METENKEFALIN)
METENKEFALIN (Guna-Virus), marketed by Guna spa, is an immunostimulant that enhances lymphocyte growth, currently holding a niche position in the market. The drug's key strength lies in its unique mechanism of action, which differentiates it from other immunostimulants. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | METENKEFALIN |
|---|---|
| Sponsor | Guna spa |
| Drug class | Lymphocyte Growth Factor [EPC] |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS (PHASE3)
- Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection (PHASE2,PHASE3)
- Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (PHASE2)
- Treatment of Advanced Head and Neck Cancer (PHASE2)
- Self-Injury: Diagnosis and Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |